# 5-Amino-1MQ Dosage: Oral Versus Subcutaneous Discussion in the Literature
> Note: PeptIQ is not a medical provider. 5-Amino-1MQ is a research compound, not a peptide in the clinical-peptide sense. This article is educational only.
The existing 5-Amino-1MQ stack guide covers NNMT inhibition and why people discuss it next to GLP-1 agonists and MOTS-c. Search still wants a dedicated 5 amino 1mq dosage page, including oral vs subQ.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor in preclinical metabolic work. That is a different evidence class from a weekly incretin trial. Dose tables on forums should be read as community habit, not as a labeled schedule.
Evidence tier
| Layer | Strength | Limit |
|---|
| Preclinical NNMT / 5-Amino-1MQ papers | Mechanism hypotheses in animals and cells | No consumer milligram label |
| Stack blogs and logs | Oral capsule versus reconstituted powder stories | Observational |
| In-app entries | What people record as mg and route | Not outcomes |
Do not invent trial PMIDs for a compound that is still mostly preclinical. If a specific paper is not already in the PeptIQ citation corpus, omit it.
Oral versus subcutaneous in community write-ups
| Route people name | Why they name it | Caution |
|---|
| Oral capsules | Convenience, daily habit, "research chem" listings | Absorption and identity are listing-dependent |
| Subcutaneous reconstituted powder | People copy peptide-vial habits | 5-Amino-1MQ is not a typical lyophilized peptide workflow |
Educational reconstitution math, if someone is holding a claimed powder, is the same generic formula as other research chemicals sold as cakes:
Concentration (mg/mL) = labeled mg ÷ diluent mL
That math does not make the powder 5-Amino-1MQ, and it does not make subcutaneous use a studied human route.
Research-reference ranges versus forum tables
Community tables often discuss daily milligram-scale oral amounts, sometimes split, sometimes stacked with a GLP-1 log or MOTS-c. Those numbers are not a starting-dose instruction. They are what dosage threads repeat.
PeptIQ users who log 5-Amino-1MQ more often record an oral daily field than an injection field. That is a logging observation.
What this page will not do
- Convert a GLP-1 weekly milligram into a 5-Amino-1MQ oral milligram
- Treat "visceral fat" marketing as a trial endpoint
- Publish a buy or source list
Related reading: the stack guide for mechanism, the MOTS-c dosing page for the mitochondrial neighbor, and NAD+ reconstitution education for the NAD-pool conversation people attach to NNMT.
Bottom line
5-Amino-1MQ dosage queries outrun the human literature. Oral versus subcutaneous is a community handling split, not a comparative trial. Figures on forums are not a protocol.
